RRMS

The beginning of the new year is an opportunity for a fresh start, change, and personal growth. Even before I was diagnosed with relapsing-remitting multiple sclerosis, I struggled deeply to allow myself moments of rest and peace, and that continues today. I’m aware of those struggles, but until now…

Cabaletta Bio is getting set to launch a clinical trial testing its cell therapy resecabtagene autoleucel (rese-cel) in people with relapsing and progressive forms of multiple sclerosis (MS). The company sought permission last year from the U.S. Food and Drug Administration (FDA) to start the study. Once such…

Patient enrollment has been completed ahead of schedule in a Phase 2 clinical trial evaluating Contineum Therapeutics‘ PIPE-307, an oral therapy aiming to restore myelin — a process known as remyelination — in people with relapsing-remitting multiple sclerosis (RRMS), the company announced. The VISTA trial (NCT06083753), launched…

Immunic Therapeutics says it remains “on track” in testing its multiple sclerosis treatment candidate vidofludimus calcium in twin Phase 3 clinical trials with people who have relapsing disease — and in the Phase 2 CALLIPER study involving those with progressive forms of MS. Indeed, in a new company…

Men with multiple sclerosis (MS) who started on high-efficacy disease-modifying therapies (DMTs) experienced significantly fewer relapses than those who started with moderate-efficacy DMTs, according to real-world claims analysis involving more than 10,000 U.S. patients. “No significant difference in relapse was found among females,” researchers wrote. “This observation highlights…

Being born and raised in south-central Texas, I’m no stranger to the heat here that dominates most of the year. But even after 25 years of living in Texas, I don’t think I’m used to it. While some people embrace and enjoy warmer weather, my body rejects it altogether, especially…

I was diagnosed with relapsing-remitting multiple sclerosis at 17 years old, during my senior year of high school. At that time, the diagnosis was the least of my worries because my top priorities were senior year activities and college preparation. The truth, however, was that I didn’t comprehend what…

A large majority of people with relapsing-remitting multiple sclerosis (RRMS) who received Tysabri (natalizumab) in a real-world setting experienced no evidence of disease activity for as long as six years, according to a study from a single center in Hungary. No evidence of disease activity, known as NEDA-3,…

In recent months, while seeking to balance work, home life, family, and well-being, I’ve sought strategies to help me tackle perfectionism. On the health front, I’ve faced major struggles with my relapsing-remitting multiple sclerosis, secondary adrenal insufficiency, and avascular necrosis. However, to this day, my perfectionism is the most…

Percutaneous tibial nerve stimulation (PTNS), a nonsurgical treatment that delivers mild electrical impulses to a nerve in the ankle, significantly reduced bladder activity and improved sexual function for women with relapsing-remitting multiple sclerosis (RRMS), according to a clinical trial. While PTNS is designed to modulate neural mechanisms involved in…

Relapsing-remitting multiple sclerosis (RRMS) brings both highs and lows to my life. Sometimes these moments will fluctuate throughout the day, while other times, the highs and lows can last for days at a time. When I experience a sustained low, I’ll find myself stuck in bed with no energy…

As a native Floridian, I’ve been through my fair share of hurricanes. Because they’re so familiar, I’m probably a bit too indifferent to them. But in many ways, hurricanes parallel my life with relapsing-remitting multiple sclerosis (RRMS); each involves preparation, weathering of the storm, and adjusting to the aftermath.

Being diagnosed with relapsing-remitting multiple sclerosis doesn’t necessarily mean that other health complications or conditions won’t arise. According to an article published in the journal Multiple Sclerosis and Related Disorders, multiple sclerosis (MS) patients have significantly higher rates of comorbidity and morbidity than people who don’t have…

The rate of disability progression among people with relapsing-remitting multiple sclerosis (RRMS) has slowed over the years due to advances in disease-modifying therapies (DMTs), according to a long-term analysis. Patients diagnosed in recent decades have experienced fewer progression events associated with relapses, called relapse-associated worsening (RAW), and also…

An independent data monitoring committee has recommended that the twin ENSURE Phase 3 trials testing vidofludimus calcium in people with relapsing forms of multiple sclerosis (MS) continue as planned without adjustments. The opinion that the trials are worth continuing was based on a review of interim, unblinded trial…

After I was diagnosed with relapsing-remitting multiple sclerosis (MS) in 2016, I thought I’d never find a partner who understood the complexities and nuances of my condition. For years, I wondered, “If I can barely comprehend the knowns and unknowns of living with MS, how could anyone else?” Oh…

SetPoint Medical is planning to launch a clinical trial next year to investigate its nerve stimulator device, intending to support myelin repair, in people with relapsing-remitting multiple sclerosis (RRMS). The announcement comes after U.S. Food and Drug Administration (FDA) approval of an investigational device exemption, allowing the…

A sublingual formulation of cladribine, which is the active ingredient of the approved oral treatment Mavenclad, in relapsing multiple sclerosis (MS), showed comparable pharmacological properties to its name-brand counterpart. That’s according to preclinical data announced by BioNxt Solutions, the formulation’s developer, in a company press release.

Continuous treatment with Briumvi (ublituximab) over five years was associated with low rates of relapses and confirmed disability progression among people with relapsing forms of multiple sclerosis (MS), according to analyses from the open-label extension (OLE) phase of the treatment’s ULTIMATE Phase 3 trials. Relative to patients who…

A short course of treatment with Mavenclad (cladribine) can provide long-term reductions in disease activity and disability progression for as long as four years in adults with highly active, relapsing forms of multiple sclerosis (MS), according to new data from the MAGNIFY-MS studies. The majority of patients had…

The U.S. Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq), a subcutaneous, or under-the-skin, formulation of Ocrevus (ocrelizumab), for treating adults with multiple sclerosis (MS). The approval covers all the same indications as the original medication, including relapsing forms of MS — namely…

A year of treatment with the experimental BTK inhibitor fenebrutinib was safe and nearly entirely suppressed signs of disease activity, including relapses, disability progression, and brain lesions, in people with relapsing forms of multiple sclerosis (MS), according to new data from the open-label extension part of a Phase…

Two weeks ago, I was notified that one of the lesions on my brain has grown. This led me and my care team to decide it was time to switch multiple sclerosis (MS) treatments. Soon after I was diagnosed with relapsing-remitting multiple sclerosis in 2017,…

A potential treatment of relapsing-remitting multiple sclerosis (RRMS), arsenic trioxide (ATO) has been patented in the European Union based on findings in preclinical studies. Notice of an intent to grant patent EP18722530, titled “Method for treating relapsing-remitting multiple sclerosis using arsenic trioxide,” was given by the European Patent…

People with relapsing-remitting multiple sclerosis (RRMS) who drink low to moderate amounts of alcohol have significantly less disability progression in the years following diagnosis than non-drinkers, a study found. The trend was especially pronounced among women. Although the findings suggest that drinking alcohol may have beneficial effects in some…

Before I was diagnosed with relapsing-remitting multiple sclerosis at age 17, I was just a young adolescent eager to attend college but uncertain about my path. However, after my diagnosis, which happened during my senior year of high school, just a couple months before college applications were due,…

PIPE-307, an experimental oral therapy that’s currently in Phase 2 testing for relapsing-remitting multiple sclerosis (RRMS), was shown to promote myelin repair in a mouse model of multiple sclerosis (MS). The preclinical findings were published in PNAS, in the study “Targeting the muscarinic M1 receptor…

About a third of people with relapsing-remitting multiple sclerosis (RRMS) exhibit cognitive impairments, according to a review by Australian researchers of 50 previously published studies. The findings suggest that cognitive issues might be somewhat less common in RRMS than previous reports have indicated, with prior estimates ranging from approximately…

A subcutaneous, or under-the-skin, formulation of Ocrevus (ocrelizumab) received approval from the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with multiple sclerosis (MS). The approval means that people with relapsing forms of MS and those with primary progressive MS (PPMS) will now be…

The European Commission has approved a subcutaneous, or under-the-skin, formulation of Ocrevus (ocrelizumab) to treat adults with multiple sclerosis (MS). The approval makes the new formulation available in the European Union for the same indications as the original intravenous (into-the-vein) formulation, which is available to people with relapsing…